Hmdb loader
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2012-09-06 15:16:52 UTC
Update Date2021-09-14 15:45:46 UTC
HMDB IDHMDB0015646
Secondary Accession Numbers
  • HMDB0060532
  • HMDB15646
  • HMDB60532
Metabolite Identification
Common NameDesvenlafaxine
DescriptionDesvenlafaxine, also known as khedezla or pristiq, belongs to the class of organic compounds known as cyclohexanols. Cyclohexanols are compounds containing an alcohol group attached to a cyclohexane ring. In humans, desvenlafaxine is involved in the venlafaxine metabolism pathway. Desvenlafaxine is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review a significant number of articles have been published on Desvenlafaxine.
Structure
Data?1582753319
Synonyms
ValueSource
1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanolChEBI
4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenolChEBI
KhedezlaKegg
O-Desmethylvenlafaxine succinateHMDB
4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenolHMDB
Succinate, desvenlafaxineHMDB
2-(1-Hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrateHMDB
O DesmethylvenlafaxineHMDB
O Desmethylvenlafaxine succinateHMDB
O-Desmethylvenlafaxine succinate monohydrateHMDB
Succinate, O-desmethylvenlafaxineHMDB
Desvenlafaxine succinateHMDB
Monohydrate, O-desmethylvenlafaxine succinateHMDB
O Desmethylvenlafaxine succinate monohydrateHMDB
O-DesmethylvenlafaxineHMDB
PristiqHMDB
Succinate monohydrate, O-desmethylvenlafaxineHMDB
O-DesvenlafaxineHMDB
DesvenlafaxineChEBI
Chemical FormulaC16H25NO2
Average Molecular Weight263.3752
Monoisotopic Molecular Weight263.188529049
IUPAC Name4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
Traditional Namedesvenlafaxine
CAS Registry Number93413-62-8
SMILES
CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
InChI Identifier
InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
InChI KeyKYYIDSXMWOZKMP-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as cyclohexanols. Cyclohexanols are compounds containing an alcohol group attached to a cyclohexane ring.
KingdomOrganic compounds
Super ClassOrganic oxygen compounds
ClassOrganooxygen compounds
Sub ClassAlcohols and polyols
Direct ParentCyclohexanols
Alternative Parents
Substituents
  • 1-hydroxy-2-unsubstituted benzenoid
  • Cyclohexanol
  • Phenol
  • Aralkylamine
  • Monocyclic benzene moiety
  • Benzenoid
  • 1,3-aminoalcohol
  • Cyclic alcohol
  • Tertiary alcohol
  • Tertiary amine
  • Tertiary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organopnictogen compound
  • Amine
  • Organic nitrogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Ontology
Disposition

Biological location

Source

Route of exposure

Process

Naturally occurring process

Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct TypeData SourceCCS Value (Å2)Reference
[M+H]+CBM166.730932474
Predicted Molecular Properties
PropertyValueSource
Water Solubility1.4 g/LALOGPS
logP10(2.6) g/LALOGPS
logP10(2.29) g/LChemAxon
logS10(-2.3) g/LALOGPS
pKa (Strongest Acidic)10.11ChemAxon
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area43.7 ŲChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.54 m³·mol⁻¹ChemAxon
Polarizability30.32 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+163.44431661259
DarkChem[M-H]-164.01531661259

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
DesvenlafaxineCN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC12813.7Standard polar33892256
DesvenlafaxineCN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC12133.7Standard non polar33892256
DesvenlafaxineCN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC12154.4Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Desvenlafaxine,1TMS,isomer #1CN(C)CC(C1=CC=C(O[Si](C)(C)C)C=C1)C1(O)CCCCC12139.4Semi standard non polar33892256
Desvenlafaxine,1TMS,isomer #2CN(C)CC(C1=CC=C(O)C=C1)C1(O[Si](C)(C)C)CCCCC12207.6Semi standard non polar33892256
Desvenlafaxine,2TMS,isomer #1CN(C)CC(C1=CC=C(O[Si](C)(C)C)C=C1)C1(O[Si](C)(C)C)CCCCC12145.0Semi standard non polar33892256
Desvenlafaxine,1TBDMS,isomer #1CN(C)CC(C1=CC=C(O[Si](C)(C)C(C)(C)C)C=C1)C1(O)CCCCC12386.2Semi standard non polar33892256
Desvenlafaxine,1TBDMS,isomer #2CN(C)CC(C1=CC=C(O)C=C1)C1(O[Si](C)(C)C(C)(C)C)CCCCC12462.5Semi standard non polar33892256
Desvenlafaxine,2TBDMS,isomer #1CN(C)CC(C1=CC=C(O[Si](C)(C)C(C)(C)C)C=C1)C1(O[Si](C)(C)C(C)(C)C)CCCCC12624.5Semi standard non polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Desvenlafaxine GC-MS (Non-derivatized) - 70eV, Positivesplash10-0a4i-9110000000-bddb56f900488038ac8f2017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Desvenlafaxine GC-MS (2 TMS) - 70eV, Positivesplash10-0ab9-9426000000-d585011517fe757dd5ff2017-10-06Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Desvenlafaxine GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Desvenlafaxine GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Desvenlafaxine GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-QTOF , negative-QTOFsplash10-03di-0090000000-90abc876cc91a398d25d2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-QTOF , negative-QTOFsplash10-03y0-0960000000-0219d7d7ea1a46c8cfdf2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-QTOF , negative-QTOFsplash10-014i-0900000000-529d7fb237a99866f0b42017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-QTOF , positive-QTOFsplash10-03di-0090000000-ccb6c8906a1ac7d27cd62017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-QTOF , positive-QTOFsplash10-0002-0290000000-422a5daa0d4bf51308ef2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-QTOF , positive-QTOFsplash10-001i-0910000000-03ecfc411d730c35b8922017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-QTOF , positive-QTOFsplash10-001i-0900000000-d0fa1892dfaae0510ee82017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-QTOF , positive-QTOFsplash10-001m-0900000000-7515704132219cf15c782017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-ITFT , positive-QTOFsplash10-0002-0090000000-1a8bdddd358a8706e8962017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-ITFT , positive-QTOFsplash10-03di-0090000000-c218ef4ab652831ee9302017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-ITFT , positive-QTOFsplash10-06r2-4090000000-b1767a9c9c01cb43bca92017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-ITFT , positive-QTOFsplash10-0a4i-9320000000-e38b2ae07ab3cc9b76932017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-ITFT , positive-QTOFsplash10-0a4i-9600000000-edbb26312a47b22bffb72017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-ITFT , positive-QTOFsplash10-0a4i-9800000000-b41801091e3c7132fec92017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-ITFT , positive-QTOFsplash10-0a4i-9800000000-4b30d7e9d71dab81d9d72017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-ITFT , positive-QTOFsplash10-03di-0090000000-5e859f484b6e3a5560c42017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-ITFT , positive-QTOFsplash10-06r2-4090000000-ef1215dc6fc4eb904b902017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-ITFT , positive-QTOFsplash10-0a4i-9310000000-dac7bd983af34469bc5f2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Desvenlafaxine LC-ESI-ITFT , positive-QTOFsplash10-0a4i-9600000000-8ea073e198c8a9a9a5282017-09-14HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Desvenlafaxine 10V, Positive-QTOFsplash10-01ot-0090000000-8bdd9e87d70ac30b0f4b2016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Desvenlafaxine 20V, Positive-QTOFsplash10-0i01-3190000000-e9a4354f756616119ea42016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Desvenlafaxine 40V, Positive-QTOFsplash10-1003-9030000000-d873fc36430c62fd51b92016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Desvenlafaxine 10V, Negative-QTOFsplash10-03di-0090000000-3151e03b6d1268750f4e2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Desvenlafaxine 20V, Negative-QTOFsplash10-03di-1390000000-6f6b5ce6a7122f6297022016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Desvenlafaxine 40V, Negative-QTOFsplash10-052f-9810000000-cf06f7edcabc2b491fb32016-08-03Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB06700 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB06700 details
UrineDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB06700
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID111300
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkDesvenlafaxine
METLIN IDNot Available
PubChem Compound125017
PDB IDNot Available
ChEBI ID83527
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  2. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  3. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  4. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]
  5. Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS: Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs. 2009 Jan;10(1):75-90. [PubMed:19127490 ]
  6. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009 Feb;29(1):39-43. doi: 10.1097/JCP.0b013e318192e4c1. [PubMed:19142106 ]
  7. Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L: Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull. 2009;42(2):47-63. [PubMed:19629022 ]
  8. Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA: Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. 2009 Nov;24(6):296-305. doi: 10.1097/YIC.0b013e32832fbb5a. [PubMed:19779354 ]
  9. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ: Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010 Aug;71(8):1088-96. doi: 10.4088/JCP.10m06018blu. [PubMed:20797382 ]
  10. Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S: Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Ther Drug Monit. 2010 Dec;32(6):704-7. doi: 10.1097/FTD.0b013e3181f88f70. [PubMed:20926994 ]
  11. Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [PubMed:22098230 ]
  12. Berm EJ, Brummel-Mulder E, Paardekooper J, Hak E, Wilffert B, Maring JG: Determination of venlafaxine and O-desmethylvenlafaxine in dried blood spots for TDM purposes, using LC-MS/MS. Anal Bioanal Chem. 2014 Apr;406(9-10):2349-53. doi: 10.1007/s00216-014-7619-9. Epub 2014 Feb 4. [PubMed:24493333 ]
  13. Murrell MD, Cruz DA, Javors MA, Thompson PM: Distribution of venlafaxine, O-desmethylvenlafaxine, and O-desmethylvenlafaxine to venlafaxine ratio in postmortem human brain tissue. J Forensic Sci. 2014 May;59(3):683-9. doi: 10.1111/1556-4029.12393. Epub 2014 Feb 6. [PubMed:24502274 ]
  14. ter Horst PG, Larmene-Beld KH, Bosman J, van der Veen EL, Wieringa A, Smit JP: Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy. J Clin Pharm Ther. 2014 Oct;39(5):541-4. doi: 10.1111/jcpt.12188. Epub 2014 Jul 3. [PubMed:24989434 ]
  15. Vignali C, Morini L, Chen Y, Stramesi C, Groppi A: Distribution of venlafaxine and O-desmethylvenlafaxine in a fatal case. Forensic Sci Int. 2014 Sep;242:e48-e51. doi: 10.1016/j.forsciint.2014.07.011. Epub 2014 Jul 21. [PubMed:25086830 ]
  16. Paulzen M, Groppe S, Tauber SC, Veselinovic T, Hiemke C, Grunder G: Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid. J Clin Psychiatry. 2015 Jan;76(1):25-31. doi: 10.4088/JCP.13m08921. [PubMed:25188033 ]
  17. (). FDA label . .
  18. (). Wyeth Laboratories Inc. Pristiq® (desvenlafaxine succinate) extended-release tablets prescribing information. Philadelphia, PA; 2010 Sept.. .
  19. PharmGKB [Link]

Enzymes

General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide.
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular weight:
57255.585

Transporters

General function:
Involved in neurotransmitter:sodium symporter activity
Specific function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular weight:
69331.42
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639 ]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900 ]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]
General function:
Involved in neurotransmitter:sodium symporter activity
Specific function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin and recycles it in a sodium-dependent manner.
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular weight:
70324.165
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639 ]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606 ]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900 ]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875 ]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767 ]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295 ]